4 The Guideline Development Group, National Collaborating Centre and NICE project team, and declarations of interests

4 The Guideline Development Group, National Collaborating Centre and NICE project team, and declarations of interests

4.1 Guideline Development Group

Gill Godsell
Nurse Consultant (Skin Cancer), Nottingham NHS Treatment Centre

Laszlo Igali
Consultant Histopathologist, Norfolk and Norwich University Hospital NHS Foundation Trust

Richard Jackson
Patient and carer member

Charles Kelly
Consultant Clinical Oncologist, Northern Centre for Cancer Care, Freeman Hospital, Newcastle

Stephen Keohane
Consultant Dermatologist, Portsmouth Hospitals NHS Trust, Portsmouth Dermatology Centre

Fergus Macbeth (Chair)
Clinical adviser, Wales Cancer Trials Unit, Cardiff University

Julia Newton‑Bishop (Clinical Lead)
Professor of Dermatology, University of Leeds

Christine Parkinson
Consultant in Medical Oncology, Addenbrooke's Hospital, Cambridge

Barry Powell
Consultant Plastic Surgeon, St George's Hospital, London

Saskia Reeken
Clinical Nurse Specialist, Skin Cancer and Dermatology, Kingston Hospital NHS Foundation Trust, Surrey

Rachael Robinson
GP, Stockwell Road Surgery, Knarlesborough, GPwSI Dermatology, Harrogate District Foundation Trust, GPwSI Durnford Dermatology, Middleton, Manchester

Simon Rodwell (from April 2013 until October 2013)
Patient and carer member

John Rouse (from November 2013)
Patient and carer member

Julia Schofield
Principal Lecturer, University of Herefordshire, Consultant Dermatologist, United Lincolnshire Hospitals NHS Trust

Jonathan Smith
Consultant Radiologist, Leeds Teaching Hospital Trust

Sara Stoneham
Paediatric and Adolescent Oncology Consultant, University College Hospital, London

Martin Telfer
Consultant Maxillofacial Surgeon, York Teaching Hospital NHS Foundation Trust

4.2 National Collaborating Centre for Cancer

Stephanie Arnold
Information Specialist

Nathan Bromham
Senior Researcher

Laura Bunting
Researcher

Andrew Champion
Centre Manager

John Graham
Director

Lianne Gwillim
Project Manager

James Hawkins
Health Economist

Coral McCarthy
Project Manager (from May 2014 until February 2015)

Angharad Morgan
Researcher

Delyth Morris
Information Specialist (until April 2014)

Susan O'Connell
Researcher

Matthew Prettyjohns
Senior Health Economist

4.3 NICE project team

Christine Carson
Guideline Lead

Mark Baker
Clinical Adviser

Katie Perryman Ford
Guideline Commissioning Manager

Jennifer Watson‑Henry
Guideline Coordinator (until November 2014)

Thomas Feist
Guideline Coordinator (from November 2014)

Nichole Taske
Technical Lead

Bhash Naidoo
Health Economist

Judy McBride
Editor

4.4 Declarations of interests

The following members of the Guideline Development Group made declarations of interests. All other members of the Group stated that they had no interests to declare. The conflicts of interest policy (2007) was followed until September 2014, when an updated policy was published.

Member

Interest declared

Type of interest

Decision taken

Barry Powell

Received a fee from Roche for chairing an advisory board on BRAF inhibitors in malignant melanoma. Donate fee to charity.

Personal pecuniary; specific

Declare and withdraw from discussions on all topics regarding BRAF inhibitors until July 2013

Barry Powell

Novartis have offered a fee to take part in a future advisory board on MEK inhibitors in melanoma. Not yet accepted.

Personal pecuniary; specific

If accepted, declare and withdraw from discussions on all topics regarding the MEK inhibitors until 12 months after date of advisory board

Barry Powell

Enrols patients into the EORTC 18091 trial. No fee received for doing this and no involvement past enrolling of patients.

Personal non‑pecuniary; specific

Declare and participate

Barry Powell

Principal investigator for the UK for the EORTC MINITUB study. Study not yet started. Funded by individual trusts.

Personal non‑pecuniary; specific

Declare and participate

Barry Powell

Chair of the Pathway Group for Skin Cancer for the London Cancer Alliance (working group on provision of skin cancer care in London).

Personal non‑pecuniary

Declare and participate

Barry Powell

Wrote an editorial for Surgery journal giving opinions on the management of malignant melanoma.

Personal non‑pecuniary

Declare and participate

Barry Powell

Received reimbursement of travelling expenses and subsistence from IGEA for attending a meeting regarding data collection for electrochemotherapy.

Personal pecuniary; specific

Declare and participate

Christine Parkinson

Received a fee from Boehringer Ingelheim for attending an advisory board and giving advice on a trial for their ovarian cancer drug BIBF1120. Fee was donated to charity.

Personal pecuniary non‑specific

Declare and participate

Christine Parkinson

Received reimbursement of registration fee and accommodation from Boehringer Ingelheim for attending the International Gynaecological Cancer Society conference.

Personal pecuniary interest, non‑specific

Declare and participate

Christine Parkinson

Co-investigator on the COMBI‑V study. Funded by GSK.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co‑investigator on PACMEL. Sponsored by University of Oxford. Funded by GSK.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co‑investigator on the Phase 1, Open Label, Dose Finding Study to Assess the Safety and Tolerability of IMCgp100, a Monoclonal T Cell Receptor Anti-CD3 scFv Fusion Protein in Patients With Advanced Malignant Melanoma. Sponsored and funded by Immunocore Ltd.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co‑investigator on NICAM. Sponsored by Royal Marsden Foundation Trust and Institute of Cancer Research. Funded by CTAAC.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co‑investigator on the IMAGE study. Funded by Bristol Myers Squibb.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co-investigator on the SUAVE study. Sponsor is Clatterbridge Centre for Oncology NHS Trust. Funded by Pfizer Limited and CTAAC.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Co-investigator on the MelResist study. Funded by Cambridge University Hospitals NHS Foundation Trust.

Non‑personal pecuniary; specific

Declare and participate

Christine Parkinson

Principle investigator on the PARAGON trial. Sponsored by NHS Greater Glasgow & Clyde. Funded by CRUK.

Non‑personal pecuniary; non‑specific

Declare and participate

Christine Parkinson

Received reimbursement of travel and subsistence expenses from CLOVIS for attending an investigator meeting for the ARIEL2 and ARIEL3 trials for ovarian cancer.

Personal pecuniary; non‑specific

Declare and participate

Fergus Macbeth

Chief investigator of a CRUK‑funded trial supported by Pfizer with free drug and unrestricted educational grant.

Non‑personal pecuniary; non‑specific

Declare and participate

Fergus Macbeth

Received reimbursement of travel and subsistence expenses for attending the World Lung Cancer conference.

Personal pecuniary, non‑specific

Declare and participate

Gill Godsell

Received reimbursement of travel and subsistence expenses from Almirall (manufacturers of topical treatments for pre-cancerous lesions) for attending a European Academy of Dermatology and Venerology meeting.

Personal pecuniary; specific

Declare and participate

Gill Godsell

Vice Chair of the Karen Clifford Skin Cancer Charity, until November 2013. Gave advice on clinical aspects of skin cancer – not specific treatments.

Personal non‑pecuniary

Declare and participate

Jonathan Smith

Reviewed a systematic review on PET-CT in stage III melanoma for publication in the Journal of Surgical Oncology.

Personal non‑pecuniary; specific

Declare and participate

Jonathan Smith

Received reimbursement of subsistence and course fee from Nucletron for attending the annual UK prostate brachytherapy course.

Personal pecuniary; non‑specific

Declare and participate

Jonathan Smith

Received travel and accommodation from the Royal College of Radiologists to give a lecture on 'how to run a radiology discrepancy' at the Royal College of Radiology autumn scientific meeting.

Personal pecuniary; non‑specific

Declare and participate

Jonathan Smith

Reports CT studies in the STAR trial, which is an RCT multi‑centre trial in drug therapy for metastatic renal cell cancer.

Non‑specific

Declare and participate

Julia Newton‑Bishop

Received an honorarium from Roche for giving advice on cutaneous toxicity from vemurafenib.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Department research fund received payment from Roche for giving advice on cutaneous toxicity from vemurafenib.

Non‑personal pecuniary

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Irish Association of Dermatologists for giving a talk on vitamin D and melanoma.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received an honorarium from Irish Association of Dermatologists for giving a talk on vitamin D and melanoma.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from the Melanoma Study Group for giving a talk at the Focus on Melanoma conference on the levels of vitamin D in melanoma patients.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Beatson Institute for attending a seminar and giving a talk on the genetics of susceptibility and survival of melanoma.

Personal pecuniary

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from London Strategic Health Authority for attending an ECRIC Cancer Registry meeting to discuss NCIN work designed to understand cancer registration.

Personal pecuniary; non‑specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Public Health England for chairing an NCIN Chair's meeting regarding national data collection on skin cancer.

Personal pecuniary; non‑specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Public Health England for chairing the skin SSCRG group covering national data collection on skin cancer.

Personal pecuniary; non‑specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from conference organisers giving a talk on the genetics of melanoma survival at the 8th World Congress of Melanoma.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Public Health England for chairing an NCIN workshop on national data collection on skin cancer.

Personal pecuniary; non‑specific

Declare and participate

Julia Newton‑Bishop

Received reimbursement of travelling expenses from Roche for attending a meeting and giving a talk on the biology of melanoma.

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Department received payment from Roche for giving an introductory talk on the biology of melanoma.

Non‑personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received an honorarium from Roche for attending an advisory board meeting on the management of skin toxicity (April 2011).

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Received an honorarium from Roche for attending an advisory board meeting on the management of skin toxicity (July 2011).

Personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Department received payment from Roche for attending an advisory board meeting on the management of skin toxicity.

Personal pecuniary; specific

Declare and participate

Julia Newton-Bishop

Department received payment from Roche for making a training video on the management of skin toxicity.

Non‑personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Department received payment from Roche for giving a talk on 'why do people get melanoma and what determines whether or not they survive' at the annual British Association of Dermatologists conference.

Non‑personal pecuniary; specific

Declare and participate

Julia Newton‑Bishop

Co‑author on paper published in 2013 regarding the toxicity of vemurafenib.

Personal non‑pecuniary

Declare and participate

Julia Schofield

Received a fee from Basilea for giving advice on their product toctino (treatment for hand eczema) into the marketplace.

Personal pecuniary; non‑specific

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from Leo Pharmaceuticals for giving a lecture on GPs with a special interest.

Personal pecuniary

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from the British Dermatology Nursing Group for giving a lecture on dermoscopy and teledermatology in relation to skin cancer (including melanoma).

Personal pecuniary; specific

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from the Dowling Club (national dermatology educational society) to present at a meeting for dermatology trainees on delivering dermatology services.

Personal pecuniary; non‑specific

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from the Primary Care Dermatology Society for presenting at a meeting on the management of pre-cancerous lesions in primary care.

Personal pecuniary; non‑specific

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from the Irish Primary Care Dermatology Society for presenting at a meeting on recognising skin lesions and paediatric dermatology problems.

Personal pecuniary;, non‑specific

Declare and participate

Julia Schofield

During 2012, acted as an advisor to Buckinghamshire NHS Trust on redesigning their dermatology services.

Personal pecuniary; non‑specific

Declare and participate

Julia Schofield

External advisor to All Party Parliamentary Group on Skin.

Personal non‑pecuniary

Declare and participate

Julia Schofield

Trustee of the Psoriasis Association.

Personal non‑pecuniary

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from Leo Pharmaceuticals for giving a lecture on GPs with a special interest.

Personal pecuniary interest

Declare and participate

Julia Schofield

Received travel and subsistence from Conference Plus for giving a lecture to GPs in Namibia on non‑melanoma skin cancer, eczema and topical dermatology.

Personal pecuniary

Declare and participate

Julia Schofield

Received a fee and reimbursement of travel expenses from the Irish Primary care Dermatology Society for giving talks on hyperhidrosis, skin lesion recognition and optimising primary/secondary care.

Personal pecuniary interest

Declare and participate

Laszlo Igali

Received a fee from St James' University Hospital, Leeds for speaking at a symposium on alopecia and immunohistochemistry in dermatopathology.

Personal pecuniary, non‑specific

Declare and participate

Laszlo Igali

Received reimbursement of travelling expenses from the Royal College of Pathologists for attending a council meeting.

Personal pecuniary

Declare and participate

Laszlo Igali

Involved in the EUR‑GAST II study (investigating environmental factors, H. pylori infection and genetic susceptibility in gastric cancer risk in the European population). Was the pathologist responsible for coordinating specimen collection and evaluation from the UK. No commercial funding.

Non‑personal pecuniary; non‑specific

Declare and participate

Laszlo Igali

Involved in the EPIC study. Did selective pathology data collection and evaluation. No commercial funding.

Non‑personal pecuniary

Declare and participate

Laszlo Igali

Supervised an MSc student investigating optimal fixation of metastatic melanoma for tissue banking.

Non‑personal pecuniary; specific

Declare and participate

Laszlo Igali

Involved in a new prospective study looking at BRAF immunostaining in metastatic melanoma to stratify patients for future treatment. Role is to do the immunohistochemistry and report on the BRAF status. Research funded by employer.

Non‑personal pecuniary; specific

Declare and participate

Laszlo Igali

Ran a workshop on teledermatopathology as part of the American Society of Dermatopathology annual congress. No fee received for this activity.

Personal non‑pecuniary

Declare and participate

Laszlo Igali

Holds the post of Editor of the Bulletin of the Royal College of Pathology.

Personal non‑pecuniary

Declare and participate

Laszlo Igali

Provides ad‑hoc advice to EZDerm on developing an integrated dermatology/ electronic record system. No fee received for this activity.

Personal non‑pecuniary

Declare and participate

Laszlo Igali

Member of the Interim Body to the Professional Records Standard Body. Provides IT advice on how their electronic records should be set up.

Personal non‑pecuniary

Declare and participate

Laszlo Igali

Received travelling expenses and accommodation from the British Association of Plastic, Reconstructive and Aesthetic Surgeons (BAPRAS) for giving a lecture at the Skin Cancer course on Basal cell carcinoma and squamous cell carcinoma, conventional and Mohs histology.

Personal pecuniary; non‑specific

Declare and participate

Laszlo Igali

Treasurer for the professional record standard body (PRSB) for patient data standards.

Personal non‑pecuniary

Declare and participate

Martin Telfer

Gave a presentation on 'Anatomical restrictions in the surgical excision of Scalp Sq CCa: does this effect local recurrence and regional nodal metastasis?' to the British Association of Oral and Maxillofacial Surgeons. No fee received.

Personal non‑pecuniary

Declare and participate

Martin Telfer

Presented at the Yorkshire & Humber Regional Clinical Effectiveness Meeting on 'Facial skin cancer surgery: patient satisfaction'. No fee received.

Personal non‑pecuniary

Declare and participate

Rachael Robinson

Received a fee from the RCGP for taking part in a panel reviewing a musculoskeletal e‑learning package.

Personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Received a fee from Galderma for chairing an educational meeting of the Leeds Skin Club on the treatment of acne and the red face.

Personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Received reimbursement of travel expenses from the Yorkshire Deanery for attending a meeting to talk about the new curriculum for GP registrars.

Personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Practice recruits patients into the 3C – cough complications cohort study, organised by Oxford University. Practice receives an income for this activity which is shared amongst the GPs.

Non‑personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Practice recruits patients into the early arthritis study, organised by Leeds University. Practice receives an income for this activity which is shared amongst the GPs.

Non‑personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Practice recruits patients into a study on transdermal patches for the treatment of chronic pain, organised by IMS Health. Practice receives an income for this activity which is shared amongst the GPs.

Non‑personal pecuniary; non‑specific

Declare and participate

Rachael Robinson

Currently involved in reviewing an acne decision aid tool for the BMJ patient decision aid group. No fee is being received.

Personal non‑pecuniary non‑specific

Declare and participate

Sara Stoneham

Received a fee from the Royal Marsden for giving a lecture on renal tumours in paediatric oncology as part of their MSc in Oncology.

Personal pecuniary; non‑specific

Declare and participate

Sara Stoneham

Principal investigator for the CNS 9204 trial (Neuropsychological, academic and functional outcomes in survivors of infant ependymoma (UKCCSG CNS 9204)). Funded by CRUK. Not involved in designing the trial protocol.

Non‑personal pecuniary non‑specific

Declare and participate

Sara Stoneham

Was principal investigator for the GC 2005 04 (GC‑3) trial (Protocol for the treatment of Extracranial Germ Cell Tumours in children and adolescents). Trial closed in 2009, 1 patient still in follow up. Sponsored by University Hospitals of Leicester NHS Trust. Funded by Children's Cancer and Leukaemia Group (CCLG).

Non‑personal pecuniary; non‑specific

Declare and participate

Sara Stoneham

Co‑investigator in the HERBY trial (study of high grade paediatric glioma). Funded by Roche.

Non‑personal pecuniary; non‑specific

Declare and participate

Saskia Reeken

Received an honorarium from Leo Pharmaceuticals for attending an advisory board on dermatology (their psoriasis treatments and new products – none relating to melanoma).

Personal pecuniary, non‑specific

Declare and participate.

Saskia Reeken

Received an honorarium from the British Dermatology Nursing Group for giving a lecture on topical treatments for dermatology (specifically steroid creams).

Personal pecuniary; non‑specific

Declare and participate

Saskia Reeken

Received reimbursement of travel expenses (from the organiser) for attending the British Association of Dermatology Nursing annual conference.

Personal pecuniary; non‑specific

Declare and participate

Saskia Reeken

Received a fee from Janssen for giving a lecture to dermatology nurses on the recognition of skin cancer lesions (including melanoma) in patients with psoriasis and the practical skills for lymph node examination.

Personal pecuniary; specific

Declare and withdraw from discussions on all topics regarding the recognition of melanoma until May 2013

Saskia Reeken

Received reimbursement of travel and subsistence expenses from the Danish Embassy in Copenhagen for attending a meeting on sun radiation and the effect on the environment.

Personal pecuniary; non‑specific

Declare and participate

Saskia Reeken

Member of the CRUK Sun Smart Advisory Board – looks at strategies for sun awareness and health promotion.

Personal non‑pecuniary

Declare and participate

Saskia Reeken

Member of the Melanoma Task Force – interested in improving the care of patients with melanoma.

Personal non‑pecuniary

Declare and participate

Saskia Reeken

Nurse representative on the British Association of Dermatology skin cancer committee.

Personal non‑pecuniary

Declare and participate

Saskia Reeken

Nurse representative on Skin Cancer UK – provides advice on skin cancer issues.

Personal non‑pecuniary

Declare and participate

Saskia Reeken

Received sponsorship from LEO pharmaceuticals and Dermal Laboratories Limited for attending a study day on Maximising Capacity and Productivity in your Dermatology Service.

Personal pecuniary; non‑specific

Declare and participate

Saskia Reeken

Received a practice development award of £900 from the British Dermatology Nursing Group. The award is to be used for professional development and will be put towards an MSc module of child health.

Personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Received a fee from Meda for attending an advisory board on their new treatment for actinic keratosis (Zyclara).

Personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Received a fee from Almirall for giving a lecture on new advances in non‑melanoma skin cancer.

Personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Received a fee from Leo Pharmaceuticals for attending an advisory board on their new treatment for actinic keratosis (Picato).

Personal pecuniary, non‑specific

Declare and participate

Stephen Keohane

Received a fee from Roche for attending an advisory board on their treatment for advanced basal cell carcinoma (Erivedge).

Personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Received reimbursement of expenses (travel, accommodation, subsistence and conference fee) from Leo Pharmaceuticals for attending the American Academy of Dermatology conference.

Personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Local principal investigator for a trial on Ingenol (treatment of facial and scalp actinic keratoses). Trial is funded by Leo Pharmaceuticals. Responsible for administrating the trial locally. Not involved in designing the trial protocol.

Non‑personal pecuniary; non‑specific

Declare and participate

Stephen Keohane

Chaired a meeting on advanced melanoma management (content of the meeting was investigation and management and covered new therapeutic treatments including ipilimumab, vemurafenib, MEK inhibitors and DNA vaccines. The event was sponsored by Bristol Myers Squibb. Did not receive a fee or organise the meeting.

Personal non‑pecuniary

Declare and participate

Stephen Keohane

Member of the National Cancer Intelligence Network Skin Reference Group – look at changing trends in skin cancer and how these impact on service provision.

Personal non‑pecuniary

Declare and participate

Stephen Keohane

Chair of the British Association of Dermatologists Skin Cancer Committee – look at service provision and ensuring the quality of skin cancer care provided by dermatologists is equitable across the UK.

Personal non‑pecuniary

Declare and participate

Stephen Keohane

Chair of the Skin Cancer Site Specific Group of the Central South Coast Cancer Network – look at local service provision and coordinate regional audits etc.

Personal non‑pecuniary

Declare and participate

John Rouse

Member of the NCRI/AstraZeneca patient reference panel.

Personal non‑pecuniary

Declare and participate

John Rouse

Received travelling expenses, subsistence allowance and overnight accommodation for a NCRI/AstraZeneca patient reference meeting at Alderley Park on 26 September 2013.

Personal pecuniary; non‑specific

Declare and participate

John Rouse

Received travelling expenses, subsistence allowance and overnight accommodation from ESO and M-icab for attending a conference on Patient Participation in Melanoma Clinical Research.

Personal pecuniary; specific

Declare and participate

John Rouse

Received a bursary from the NCRN to attend the NCRI conference in Liverpool

Personal pecuniary

Declare and participate

John Rouse

Received travelling expenses, overnight accommodation and subsistence allowance paid for by CRUK for attending the NCRN/ECMC Combinations Alliance AZ Workshop.

Personal pecuniary

Declare and participate

John Rouse

Received travelling expenses costs from Macmillan Cancer support and accommodation costs from the meeting organisers for attending the Britain Against Cancer conference and Quality in Care awards.

Personal pecuniary

Declare and participate

Richard Jackson

Interviewed for the Daily Mail on the effectiveness of ipilimumab for metastatic melanoma.

Personal non‑pecuniary

Declare and participate

Richard Jackson

Interviewed for the BBC on medical breakthroughs and the use of Ipilimumab received during treatment.

Personal non‑pecuniary

Declare and participate

Richard Jackson

Photographed and filmed by Bristol‑Myers Squibb Pharmaceuticals Ltd. Discussed his experience of metastatic melanoma. Film is to be used by BMS to make colleagues more aware of patients' unmet medical needs. No payment received.

Personal non‑pecuniary

Declare and participate.

Julia Schofield

Received travel and accommodation costs from Conference Plus for giving a lecture in an educational programme for GPs. The lecture includes a session on skin lesion diagnosis.

Non‑personal pecuniary; non‑specific

Declare and participate

John Rouse

Received a bursary from the NCRN to attend the NCRI conference in Liverpool.

Personal pecuniary; non‑specific

Declare and participate

John Rouse

Received travelling expenses, overnight accommodation and subsistence allowance paid for by CRUK for attending the NCRN/ECMC Combinations Alliance AZ Workshop.

Personal pecuniary; non‑specific

Declare and participate

John Rouse

Received travelling expenses costs from Macmillan Cancer support and accommodation costs from the meeting organisers for attending the Britain Against Cancer conference and Quality in Care awards.

Personal pecuniary; non‑specific

Declare and participate

  • National Institute for Health and Care Excellence (NICE)